Adverse events following immunization in children: Retrospective analysis of spontaneous reports over a decade

European Journal of Clinical Pharmacology

Volumn 67, Issue 3, 2011, Pages 283-288

  Aagaard, Lise ^a   Hansen, Erik Wind ^a   Hansen, Ebba Holme ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Children; Denmark; Immunization; Pharmacoepidemiology; Vaccines

Indexed keywords

ACT HIB; DIPLOID CELL VACCINE; DITEKIPOL; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MENINGOVAX; PNEUMOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TICK BORNE ENCEPHALITIS VACCINE; TICO VAC; TYPHOID VACCINE; UNCLASSIFIED DRUG; VACCINE; VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ARTICLE; CHILD; DANISH; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; FEBRILE CONVULSION; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNIZATION; INFANT; INFLUENZA; INFLUENZA B; INJECTION SITE REACTION; JAPANESE ENCEPHALITIS; MAJOR CLINICAL STUDY; MEASLES; MENINGOCOCCOSIS; MUMPS; NEUROLOGIC DISEASE; PNEUMOCOCCAL INFECTION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; RUBELLA; SKIN DISEASE; TICK BORNE ENCEPHALITIS; TYPHOID FEVER;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; VACCINATION; VACCINES;

EID: 79954429611     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0944-9     Document Type: Article

References (32)

1. M Letourneau G Wells W Walop P Duclos 2008 Improving global monitoring of vaccines safety. A survey of national centres participating in the WHO programme for international drug monitoring Drug Saf 31 389 398 10.2165/00002018-200831050-00003 18422379 (Pubitemid 351563731)
2. E Wendy JD Parmet 2010 Pandemic vaccines-the legal landscape N Engl J Med 362 1949 1952 10.1056/NEJMp1000938
3. KK O'Brien 2009 Pharmacists' role in preventing vaccine-preventable diseases US Pharm 34 39 45
4. D Mrożek-Budzyn A Kiełtyka R Majewska 2010 Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study Pediatr Infect Dis J 29 397 400 10.1097/INF.0b013e3181c40a8a 19952979
5. KM Madsen A Hviid M Vestergaard D Schendel J Wohlfahrt P Thorsen J Olsen M Melbye 2002 A population-based study of measles, mumps, and rubella vaccination and autism N Engl J Med 347 1477 1482 10.1056/NEJMoa021134 12421889 (Pubitemid 35257586)
6. A Hviid M Stellfeld J Wohlfahrt M Melbye 2004 Childhood vaccination and type 1 diabetes N Engl J Med 350 1398 1404 1:CAS:528:DC%2BD2cXivVagtr4%3D 10.1056/NEJMoa032665 15070789 (Pubitemid 38419993)
7. A Hviid M Melbye 2008 Measles-mumps-rubella vaccination and asthma-like disease in early childhood Am J Epidemiol 168 1277 1283 10.1093/aje/kwn253 18845551
8. E Harris 2010 After Wakefield: the real questions that need addressing Br Med J 340 c2829 10.1136/bmj.c2829
9. RM Jacobson 2003 Vaccine safety Immunol Allergy Clin N Am 23 589 03 10.1016/S0889-8561(03)00090-0 (Pubitemid 38030160)
10. A Patja I Davidkin T Kurki MJ Kallio M Valle H Peltola 2000 Serious adverse events after measles-mumpsrubella vaccination during a fourteen-year prospective follow-up Pediatr Infect Dis 19 1127 1134 1:STN:280: DC%2BD3MzitV2ntA%3D%3D 10.1097/00006454-200012000-00002 (Pubitemid 32003354)
11. O Mansoor PI Pillans 1997 Vaccine adverse events reported in New Zealand 1990-1995 NZ Med J 110 270 272 1:STN:280:DyaK2svhsVKjtg%3D%3D (Pubitemid 27344301)
12. RM D'Souza S Campbell-Lloyd D Isaacs M Gold M Burgess F Turnbull E O'Brien 2000 Adverse events following immunisation associated with the 1998 Australian measles control campaign Commun Dis Intell 24 27 33 10758692
13. G Lawrence R Menzies M Burgess N Wood I Boyd P Purcell D Isaacs 2003 Surveillance of adverse events following immunisation: Australia, 2000-2002 Commun Dis Intell 27 307 323 14510057
14. G Lawrence I Boyd P McIntyre P McIntyre D Isaacs 2004 Surveillance of adverse events following immunisation: Australia 2002 to 2003 Commun Dis Intell 28 324 338 15574056
15. G Lawrence I Boyd 2005 Supplementary report: surveillance of adverse events following immunisation among children aged less than 7 years in Australia, 1 January to 30 June 2005 Commun Dis Intell 29 413 416 16465935
16. GL Lawrence PE Aratchige I Boyd PB McIntyre MS Gold 2007 Annual report on surveillance of adverse events following immunisation in Australia, 2006 Commun Dis Intell 31 269 282 17974219
17. G Lawrence MS Gold R Hill S Deeks A Glasswell B McIntyre 2008 Annual report: surveillance of adverse events following immunisation in Australia, 2007 Commun Dis Intell 32 371 387 19374268
18. L Aagaard CB Weber EH Hansen 2010 Adverse drug reactions reported for children in Denmark from 1998-2007 Drug Saf 33 327 339 10.2165/11319100- 000000000-00000 20297864
19. L Aagaard EH Hansen 2010 Adverse drug reactions from psychotropic medicines reported for children 1998-2007: a national register-based study from Denmark BMC Res Notes 23 3 176 10.1186/1756-0500-3-176
20. L Aagaard EH Hansen 2010 Adverse drug reactions reported for systemic antibacterials in Danish children over a decade Br J Clin Pharmacol 10.1111/j.1365-2125.2010.03732.x
21. The Danish National Board of Health. The children's vaccination schedule in Denmark, 2009. Available at: ( http://www.sst.dk ). Accessed 3 June 2010
22. Summary of product information. MFR vaccine. Available at: ( http://www.smi.dk ). Accessed 3 June 2010
23. Summary of product information. Ditekipol/Act-Hib vaccine. Available at: ( http://www.smi.dk ). Accessed 3 June 2010
24. L Aagaard DI Stenver EH Hansen 2008 Structures and processes in spontaneous reporting systems: a comparative study of Australia and Denmark Pharm World Sci 30 563 570 10.1007/s11096-008-9210-y 18350372
25. Roden S, Gibbs T (2007) CIOMS Working Groups and their contribution to pharmacovigilance. In: Mann RD, Andrews EB (eds) Pharmacovigilance, 2nd edn, chapter 23. John Wiley & Sons, Chichester, pp 287-305
26. MedDRA. Available at: http://www.meddramsso.com (last accessed June 3 2010) [password required]
27. Pharmacovigilance: medicinal products for human use and veterinary products, vol. 9. Available at: http://ec.europa.eu/enterprise/pharmaceuticals/ eudralex/homev9.htm. Accessed 3 April 2010
28. Infomedia. Available at: http://www.infomedia.dk. Accessed 20 November 2009
29. S Glissman 2005 Danish Supreme Court rules that child with autism developed in temporal relation with MMR vaccination is not entitled to compensation Euro Surveill 10 E050428.3
30. A Hviid M Stellfeld J Wohlfahrt PH Andersen M Melbye 2006 The impact of pre-school booster vaccination of 4-6-year-old children on pertussis in 0-1-year-old children Vaccine 27 1401 1407 10.1016/j.vaccine.2005.09.019 (Pubitemid 43222050)
31. L Aagaard EH Hansen 2009 Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs BMC Clin Pharmacol 3 9 4 10.1186/1472-6904-9-4
32. EJ Woo R Ball DR Burwen MM Braun 2008 Effects of stratification on data mining in the US Vaccine adverse event reporting system (VAERS) Drug Saf 31 667 674 10.2165/00002018-200831080-00003 18636785 (Pubitemid 352019564)